Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Unknown 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Mesothelioma 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1362Gemcitabine 1235Bevacizumab 1226Paclitaxel 1214Radiotherapy 1176Docetaxel 1080pembrolizumab 1029Oxaliplatin 936Capecitabine 902Fluorouracil 833Rituximab 729Doxorubicin 684Nivolumab 679Dexamethasone 667Etoposide 660Irinotecan 622Leucovorin 576Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 470Cytarabine 467Magnetic Resonance Spectroscopy 461Filgrastim 446Prednisone 433Specimen Handling 411Lenalidomide 410Vincristine 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × MAC321 × Clear all
NCT00063219 2009-08-21

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00063427 2009-08-21

Study Evaluating MAC-321 in Colorectal Cancer

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
45 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00685204 2008-05-28

TL139

Taxolog Inc.

Phase 2 Unknown
90 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡